Brammer Bio is Awarded MassEcon Impact Award

NEWS RELEASE

Brammer Bio is Awarded MassEcon Impact Award

Cambridge, MA, USA, October 23, 2017 – Brammer Bio (“Brammer”), a best-in-class cell and gene therapy contract development and manufacturing organization, has been recognized by MassEcon for outstanding contributions to the Massachusetts economy. MassEcon is a private, non-profit partnership of business, industry leaders, and government dedicated to the economic growth of Massachusetts. MassEcon’s award program is based on the categories of job growth, facility expansion, investment, and community involvement.

“We are honored to be chosen as a recipient of this award,” said Mark Bamforth, president and CEO of Brammer. “This is an opportunity to celebrate our team and recognize our commitment to diversity. It is a testament to our dedication in helping our clients succeed in delivering cutting edge therapies to their patients in need, and to Massachusetts’ commitment to fostering the long-term growth of the state’s biotechnology sector. We are also proud to be among the strong group of recipients and nominees recognized by MassEcon.”

Brammer has a diverse workforce with over 30 percent minorities and a strong focus on gender balance through a Women in Leadership program.

“Massachusetts welcomes Brammer Bio’s commercial manufacturing operations to Cambridge as the company is preserving and growing manufacturing jobs in a key business sector that will support other biotech companies in the State” said Secretary of Housing and Economic Development Jay Ash. “Maintaining strong relationships between public and private sectors is crucial to long-term economic growth, and providing community access to job opportunities across the Commonwealth.”

The company’s Massachusetts locations include Cambridge, Somerville, and Lexington. In Cambridge, Brammer preserved 100 high quality manufacturing jobs in January 2017 when it acquired two existing facilities and has hired an additional 40 employees to date. Brammer has invested $40 million into renovating its Cambridge facility to manufacture late-stage and commercial gene therapy products using multiple platform technologies.

Brammer has executives on the boards of MassBio, Mass Bio Educational Foundation, Wentworth Institute of Technology, West End House Boys and Girls Clubs of Boston, and is a sponsor of the Pan-Mass Challenge, and other worthy causes.


About Brammer Bio

Brammer Bio offers clinical and commercial services to supply vectors for in vivo gene therapy and ex vivo modified-cell based therapy. This includes process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients’ health. Brammer is owned by Ampersand Capital Partners, the only institutional investor in the company, and its founders. For more information, please visit www.brammerbio.com.

About Ampersand Capital Partners

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Visit www.ampersandcapital.com.

For media inquiries contact:
Lynn Costa
lynn.costa@brammerbio.com
Media: +1 781 924 6551

Brammer Bio address:
250 Binney Street
Cambridge, MA 02142

Brammer Bio website and contact info:
www.brammerbio.com
Sales inquiries: +1 866 GENE CMO (436 3266)
E-mail: info@brammerbio.com